Bioavailability Study Guide

📖 Core Concepts Bioavailability (F or f) – fraction of an administered dose that reaches systemic circulation; expressed as a decimal (0‑1) or %. Absolute bioavailability – compares systemic exposure after a non‑IV route to IV exposure, correcting for dose differences. Relative bioavailability – compares AUC of two formulations of the same drug (or nutrient). Area Under the Curve (AUC) – integral of plasma concentration vs. time; proportional to the amount of drug that entered the bloodstream. Bioequivalence – a generic must show its AUC and Cmax are within 80‑125 % of the reference product (90 % CI). 📌 Must Remember IV route = 100 % bioavailability (no absorption barriers). Absolute bioavailability formula $$F = \frac{\text{AUC}{\text{non‑IV}} / \text{Dose}{\text{non‑IV}}}{\text{AUC}{\text{IV}} / \text{Dose}{\text{IV}}}$$ FDA bioequivalence limits: 90 % CI for AUC and Cmax must fall within 80 %–125 % of the reference. Key PK parameters: AUC – total exposure. Cmax – peak plasma concentration. Tmax – time to reach Cmax. Variability handling: use the lower limit of the reported deviation range when dosing drugs with a narrow therapeutic window. 🔄 Key Processes Determine Absolute Bioavailability Administer drug IV → collect plasma‑time data → calculate AUC\({IV}\). Administer same drug by the test route (oral, etc.) → collect plasma‑time data → calculate AUC\({non‑IV}\). Normalize each AUC by its respective dose. Plug into the formula above to obtain F. Conduct a Bioequivalence Study Recruit healthy volunteers, give reference product → obtain AUC\({ref}\), Cmax\({ref}\). After wash‑out, give test formulation → obtain AUC\({test}\), Cmax\({test}\). Compute the ratio (test/reference) for AUC and Cmax. Perform ANOVA → derive 90 % confidence intervals; accept if both lie within 80‑125 %. 🔍 Key Comparisons Absolute vs. Relative Bioavailability Absolute: compares to IV reference; needed for new chemical entities. Relative: compares two non‑IV formulations of the same molecule; used for generics & nutrient formulations. AUC vs. Cmax AUC: measures total exposure (extent of absorption). Cmax: measures peak concentration (rate of absorption). ⚠️ Common Misunderstandings “Higher Cmax = better efficacy.” Cmax only reflects rate; efficacy is usually linked to AUC (total exposure). “Oral = 100 % if the drug is “well‑absorbed.” First‑pass metabolism can still lower F even with good intestinal uptake. “Bioequivalence guarantees identical clinical effect.” Therapeutic equivalence is assumed but may differ in special populations (e.g., extreme pH, enzyme polymorphisms). 🧠 Mental Models / Intuition “Pipeline analogy” – Think of the drug as water flowing through a pipeline: IV injects directly into the main pipe (100 %); oral must pass through valves (stomach, intestine) and a filter (first‑pass liver), losing some water at each step. “AUC as the bucket” – The larger the bucket (area under the curve), the more drug has actually entered the system, regardless of how fast it got there. 🚩 Exceptions & Edge Cases Highly lipophilic drugs may undergo extensive first‑pass metabolism, giving very low oral F despite good membrane permeability. Enterohepatic recirculation can create secondary peaks, inflating AUC without increasing true absorption. Nutrient supplements: absorption can be dramatically altered by nutritional status (e.g., iron absorption ↑ with deficiency). 📍 When to Use Which Use absolute bioavailability when you need to compare a new route or formulation to the gold‑standard IV exposure (new drug development, regulatory submission). Use relative bioavailability for: Generic drug approval (bioequivalence). Comparing nutrient formulations (e.g., different calcium salts). Choose AUC vs. Cmax as primary metric based on therapeutic goal: Chronic therapy: prioritize AUC (overall exposure). Rapid‑onset therapy: Cmax and Tmax become more critical. 👀 Patterns to Recognize Low F + high lipophilicity + basic pKa → suspect extensive first‑pass metabolism or P‑gp efflux. Food effect → delayed Tmax & increased AUC → likely improved solubility or reduced first‑pass metabolism. Bioequivalence study results where the 90 % CI barely fits within 80‑125 % often indicate formulation differences that could matter clinically in vulnerable patients. 🗂️ Exam Traps Choosing “Cmax” instead of “AUC” for bioequivalence – the FDA requires both AUC and Cmax to fall within limits; a single‑parameter answer is incomplete. Assuming “oral = 100 %” because a drug is listed in Lipinski’s Rule of Five – Lipinski predicts potential permeability, not actual systemic exposure after first‑pass loss. Confusing “relative bioavailability” with “absolute” – remember relative always compares two non‑IV formulations of the same entity; absolute always involves an IV reference. Ignoring dose normalization – plugging raw AUC values into the formula without dividing by dose yields an incorrect F. --- Keep this sheet handy; the formulas, thresholds, and the “pipeline” intuition will let you answer most bioavailability questions quickly and confidently.